Department of Radiology, University Hospital, LMU Munich, Munich, Germany; Comprehensive Pneumology Center (CPC-M), University Hospital, LMU Munich, Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany.
Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Z Med Phys. 2022 Feb;32(1):74-84. doi: 10.1016/j.zemedi.2020.09.004. Epub 2020 Nov 25.
Ventilation-induced tumour motion remains a challenge for the accuracy of proton therapy treatments in lung patients. We investigated the feasibility of using a 4D virtual CT (4D-vCT) approach based on deformable image registration (DIR) and motion-aware 4D CBCT reconstruction (MA-ROOSTER) to enable accurate daily proton dose calculation using a gantry-mounted CBCT scanner tailored to proton therapy.
Ventilation correlated data of 10 breathing phases were acquired from a porcine ex-vivo functional lung phantom using CT and CBCT. 4D-vCTs were generated by (1) DIR of the mid-position 4D-CT to the mid-position 4D-CBCT (reconstructed with the MA-ROOSTER) using a diffeomorphic Morphons algorithm and (2) subsequent propagation of the obtained mid-position vCT to the individual 4D-CBCT phases. Proton therapy treatment planning was performed to evaluate dose calculation accuracy of the 4D-vCTs. A robust treatment plan delivering a nominal dose of 60Gy was generated on the average intensity image of the 4D-CT for an approximated internal target volume (ITV). Dose distributions were then recalculated on individual phases of the 4D-CT and the 4D-vCT based on the optimized plan. Dose accumulation was performed for 4D-vCT and 4D-CT using DIR of each phase to the mid position, which was chosen as reference. Dose based on the 4D-vCT was then evaluated against the dose calculated on 4D-CT both, phase-by-phase as well as accumulated, by comparing dose volume histogram (DVH) values (D, D, D, D) for the ITV, and by a 3D-gamma index analysis (global, 3%/3mm, 5Gy, 20Gy and 30Gy dose thresholds).
Good agreement was found between the 4D-CT and 4D-vCT-based ITV-DVH curves. The relative differences ((CT-vCT)/CT) between accumulated values of ITV D, D, D and D for the 4D-CT and 4D-vCT-based dose distributions were -0.2%, 0.0%, -0.1% and -0.1%, respectively. Phase specific values varied between -0.5% and 0.2%, -0.2% and 0.5%, -3.5% and 1.5%, and -5.7% and 2.3%. The relative difference of accumulated D over the lungs was 2.3% and D for the phases varied between -5.4% and 5.8%. The gamma pass-rates with 5Gy, 20Gy and 30Gy thresholds for the accumulated doses were 96.7%, 99.6% and 99.9%, respectively. Phase-by-phase comparison yielded pass-rates between 86% and 97%, 88% and 98%, and 94% and 100%.
Feasibility of the suggested 4D-vCT workflow using proton therapy specific imaging equipment was shown. Results indicate the potential of the method to be applied for daily 4D proton dose estimation.
在肺部患者的质子治疗中,呼吸诱导的肿瘤运动仍然是精确性的挑战。我们研究了使用基于变形图像配准(DIR)和运动感知 4D CBCT 重建(MA-ROOSTER)的 4D 虚拟 CT(4D-vCT)方法的可行性,该方法使用定制的质子治疗龙门架 CBCT 扫描仪来实现准确的日常质子剂量计算。
使用 CT 和 CBCT 从猪离体功能性肺模型中获取 10 个呼吸阶段的相关数据。通过(1)使用 Morphons 算法将中位置 4D-CT 与中位置 4D-CBCT(使用 MA-ROOSTER 重建)的 DIR,以及(2)随后将获得的中位置 vCT 传播到各个 4D-CBCT 相位,生成 4D-vCT。进行质子治疗计划,以评估 4D-vCT 的剂量计算准确性。在 4D-CT 的平均强度图像上生成一个稳健的治疗计划,为近似的内部靶区(ITV)提供 60Gy 的名义剂量。然后根据优化的计划,在 4D-CT 和 4D-vCT 的各个相位上重新计算剂量分布。对于 4D-vCT 和 4D-CT,使用每个相位到中位置的 DIR 进行剂量积累,中位置被选为参考。然后,通过比较 ITV 的剂量体积直方图(DVH)值(D、D、D、D)以及通过三维伽马指数分析(全局、3%/3mm、5Gy、20Gy 和 30Gy 剂量阈值),将基于 4D-vCT 的剂量与基于 4D-CT 的计算剂量进行评估。
在 4D-CT 和基于 4D-vCT 的 ITV-DVH 曲线之间发现了良好的一致性。对于 ITV 的 D、D、D 和 D 的累积值,4D-CT 和 4D-vCT 基于剂量分布的相对差异((CT-vCT)/CT)分别为-0.2%、0.0%、-0.1%和-0.1%。相位特异性值在-0.5%和 0.2%、-0.2%和 0.5%、-3.5%和 1.5%以及-5.7%和 2.3%之间变化。累积的 D over lungs 的相对差异为 2.3%,相位的 D 变化范围为-5.4%至 5.8%。累积剂量的 5Gy、20Gy 和 30Gy 阈值的伽马通过率分别为 96.7%、99.6%和 99.9%。相位比较的通过率在 86%至 97%、88%至 98%和 94%至 100%之间。
使用质子治疗专用成像设备的建议 4D-vCT 工作流程的可行性得到了证明。结果表明,该方法有可能应用于日常 4D 质子剂量估计。